H.R. 2818: Methamphetamine Education, Treatment, and Hope Act

H.R. 2818

Methamphetamine Education, Treatment, and Hope Act

Sponsor
Rep. Jerry McNerney

Date
September 28, 2010 (111th Congress, 2nd Session)

Staff Contact
Communications

Floor Situation

H.R. 2818 is expected to be considered on the House floor on Wednesday, September 29, 2010, under a suspension of the rules, requiring a two-thirds majority vote to pass.  Rep. McNerney (D-CA) introduced H.R. 2818 on June 11, 2009, and it was referred to the Committee on Energy and Commerce. 

Bill Summary

H.R. 2818 would require the director of the Center for Substance Abuse Treatment to collaborate with primary health care providers and professionals in the addiction field to raise awareness about how to: (1) recognize the signs of a substance abuse disorder and (2) apply evidence-based practices for screening and treating individuals with, or at-risk for developing, an addiction to drugs.

 

The bill would revise a grant program for substance abuse residential treatment for pregnant and parenting women to do the following: (1) include treatment for addiction to methamphetamine, outpatient treatment services and referrals for dental services and (2) require programs to be accessible to pregnant and parenting women in low-income households and in health disparity populations.  The director would give priority to programs using the following criteria: (1) a rural area, an area with a shortage of mental health professionals, or an area with a shortage of family-based substance abuse treatment options and (2) has high rates of addiction to methamphetamine or other drugs.

 

The bill would require the director of the Office for Substance Abuse Prevention to develop a drug-free workplace clearinghouse that provides information and educational materials to employers and employers about drug-testing policies and programs.

 

The bill would develop a student-driven methamphetamine awareness project. 

 

H.R. 2818 would authorize $16 million to be appropriated for fiscal year 2012, $16.5 million for fiscal year 2013, $17,000,000 million for fiscal year 2014, $17,500,000 for fiscal year 2015, and $18,000,000 for fiscal year 2016.   

Background

Methamphetamine is a highly addictive stimulant that can have serious effects on a user's physical, mental, and social well-being. 

Cost

As of publication, the Congressional Budget Office had not released a score of H.R. 2818.